Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.

MLA

Peters, Solange, et al. “Entrectinib in ROS1-Positive Advanced Non-Small Cell Lung Cancer: The Phase 2/3 BFAST Trial.” Nature Medicine, vol. 30, no. 7, July 2024, pp. 1923–32. EBSCOhost, https://doi.org/10.1038/s41591-024-03008-4.

APA

Peters, S., Gadgeel, S. M., Mok, T., Nadal, E., Kilickap, S., Swalduz, A., Cadranel, J., Sugawara, S., Chiu, C.-H., Yu, C.-J., Moskovitz, M., Tanaka, T., Nersesian, R., Shagan, S. M., Maclennan, M., Mathisen, M., Bhagawati-Prasad, V., Diarra, C., Assaf, Z. J., … Dziadziuszko, R. (2024). Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. Nature Medicine, 30(7), 1923–1932. https://doi.org/10.1038/s41591-024-03008-4

Chicago

Peters, Solange, Shirish M Gadgeel, Tony Mok, Ernest Nadal, Saadettin Kilickap, Aurélie Swalduz, Jacques Cadranel, et al. 2024. “Entrectinib in ROS1-Positive Advanced Non-Small Cell Lung Cancer: The Phase 2/3 BFAST Trial.” Nature Medicine 30 (7): 1923–32. doi:10.1038/s41591-024-03008-4.